Matches in Wikidata for { <http://www.wikidata.org/entity/Q66066918> ?p ?o ?g. }
Showing items 1 to 53 of
53
with 100 items per page.
- Q66066918 description "clinical trial" @default.
- Q66066918 description "ensayu clínicu" @default.
- Q66066918 description "klinisch onderzoek" @default.
- Q66066918 description "клінічне випробування" @default.
- Q66066918 name "An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread" @default.
- Q66066918 name "An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread" @default.
- Q66066918 type Item @default.
- Q66066918 label "An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread" @default.
- Q66066918 label "An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread" @default.
- Q66066918 prefLabel "An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread" @default.
- Q66066918 prefLabel "An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread" @default.
- Q66066918 P1132 Q66066918-7D1D6E46-C39B-48D3-90CB-F907CFEE5B30 @default.
- Q66066918 P1476 Q66066918-A1900BC9-5AFB-4B07-B326-5094A32B3E55 @default.
- Q66066918 P17 Q66066918-0ED84207-5F8E-42CD-B87B-6EEA399BF1A6 @default.
- Q66066918 P17 Q66066918-132A4045-8266-4FF4-B210-6017F4D23035 @default.
- Q66066918 P17 Q66066918-16BC5E80-600E-4B73-B64A-C0BFE911956D @default.
- Q66066918 P17 Q66066918-692C1794-352F-4707-82CF-D183E89742BA @default.
- Q66066918 P17 Q66066918-6C8E6964-2434-4C7C-AB20-E39C784111F3 @default.
- Q66066918 P17 Q66066918-85D238E2-6E1A-4295-B209-22277E399E88 @default.
- Q66066918 P17 Q66066918-B09298C8-EBB8-49C8-AFFB-485B8C11B754 @default.
- Q66066918 P2899 Q66066918-9D05D719-58E9-47B1-BE27-CEB81C458162 @default.
- Q66066918 P3098 Q66066918-C56DC34E-DAA7-4029-8EEE-EBFA479179F6 @default.
- Q66066918 P31 Q66066918-DA0F6E0F-D9FF-428E-B218-FB57AB7178F0 @default.
- Q66066918 P580 Q66066918-89DE58CB-17F2-4BAD-ABBF-A987E849AACB @default.
- Q66066918 P582 Q66066918-E93D7E5B-3C4D-4B5C-AB27-188C6BA082DB @default.
- Q66066918 P6099 Q66066918-21315ED5-D4EF-44D2-8ED2-64EC2572951D @default.
- Q66066918 P6099 Q66066918-49DD6505-51E2-49EF-A733-99AF4F5B486D @default.
- Q66066918 P6153 Q66066918-6449278D-1D57-4A79-8058-7FA4B1369E8E @default.
- Q66066918 P6153 Q66066918-96EC9C75-49E4-41B0-A78D-68F14433C0C2 @default.
- Q66066918 P6153 Q66066918-AEB2E486-EEB6-4EB6-8B47-BE5923BCC7B2 @default.
- Q66066918 P8363 Q66066918-715F74E4-BD48-4F22-B748-01947DB6BAA7 @default.
- Q66066918 P859 Q66066918-09E7CD54-8C71-469D-9BD2-9A7307207092 @default.
- Q66066918 P1132 "+230" @default.
- Q66066918 P1476 "A Phase 1/2 Study of Relatlimab (Anti-LAG-3 Monoclonal Antibody) Administered in Combination With Both Nivolumab (Anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1 Inhibitor) or in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors" @default.
- Q66066918 P17 Q142 @default.
- Q66066918 P17 Q145 @default.
- Q66066918 P17 Q29 @default.
- Q66066918 P17 Q30 @default.
- Q66066918 P17 Q38 @default.
- Q66066918 P17 Q39 @default.
- Q66066918 P17 Q408 @default.
- Q66066918 P2899 "+18" @default.
- Q66066918 P3098 "NCT03459222" @default.
- Q66066918 P31 Q30612 @default.
- Q66066918 P580 "2018-05-25T00:00:00Z" @default.
- Q66066918 P582 "2022-04-04T00:00:00Z" @default.
- Q66066918 P6099 Q42824440 @default.
- Q66066918 P6099 Q5452194 @default.
- Q66066918 P6153 Q219615 @default.
- Q66066918 P6153 Q3297837 @default.
- Q66066918 P6153 Q5123723 @default.
- Q66066918 P8363 Q78089383 @default.
- Q66066918 P859 Q266423 @default.